PORTFOLIO

Abraxis Bioscience, Inc. (NASDAQ: ABBI) is a strategically integrated pharmaceutical company that manufactures, markets and develops injectable products, with a focus on oncology and anti-infectives. Acquired by Celgene.
Achillion Pharmaceuticals (NASDAQ: ACHN) is developing iron nanoparticle-based therapeutics. The company’s lead product, Feraheme, has been approved by the FDA for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion® (abuse deterrent) Technology and related product candidates. Acura’s lead product, Oxecta, has been approved by the FDA and is partnered with Pfizer.
AMAG Pharmaceuticals (NASDAQ: AMAG) is developing iron nanoparticle-based therapeutics. The company’s lead product, Feraheme, has been approved by the FDA for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.
APT Pharmaceuticals is a clinical-stage company developing products to treat respiratory diseases.
Aspreva Pharmaceuticals (NASDAQ: ASPV) is a pharmaceutical company which identifies, develops and commercializes new applications for existing medicines. Acquired by Galenica.
Avanir Pharmaceuticals (NASDAQ: AVNR) is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. The company’s lead product, Nuedexta, has been approved by the FDA for the treatment of pseudobulbar affect.
Biodel, Inc. is a biopharmaceutical drug delivery company with novel products in development for the treatment of diabetes.
BioForm Medical, Inc. is developing and commercializing Radiesse and Coaptite, proprietary gels containing calcium hydroxylapatite, for cosmetic applications, stress urinary incontinence (SUI), vocal cord insufficiency and paralysis (VFI), and other disorders. Acquired by Merz.
Biotie Therapies (NASDAQ: BITI) is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. Acquired by Acorda.
Ceptaris Therapeutics is a privately held specialty pharmaceutical company developing a product for the treatment of cutaneous T-cell lymphoma (CTCL). Acquired by Actelion.
Chelsea Therapeutics (NASDAQ: CHTP) acquires, develops and commercializes innovative products for the treatment of important unmet medical needs such as rheumatoid arthritis, psoriasis, and other inflammatory conditions.
CoTherix (NASDAQ: CTRX) is marketing Ventavis® (iloprost aerosol) for the treatment of primary pulmonary hypertension, an orphan indication, for the U.S. market. Acquired by Actelion.
Durata Therapeutics (NASDAQ: DRTX) is a pharmaceutical company focused on the development and commercialization of therapeutic solutions in infectious disease.
Dynavax Technologies (NASDAQ: DVAX) is a clinical-stage biopharmaceutical company committed to discovering and developing novel products to prevent and treat infectious diseases.
Essentialis is developing a novel therapy for the treatment of dyslipidemia.
Hamilton Pharmaceuticals, Inc. (HPI) is developing novel treatments for central nervous system disease. Acquired by Neuren.
InterMune (NASDAQ: ITMN) is a biopharmaceutical company focused on the applied research, development and marketing of life-saving therapies for pulmonary diseases.
MacroGenics (NASDAQ: MGNX) is developing antibodies and vaccines in the areas of oncology, inflammation, allergy, and infectious diseases.
MEI Pharma (NASDAQ: MEIP) is focused on the clinical development of novel therapies for cancer. MEI’s programs include a potential best-in-class HDAC inhibitor, Pracinostat, and isoflavone-based compounds ME-143 and ME-344.
NeoMend, Inc. is a medical device company commercializing ProGel Pleural Air Leak Sealant for lung air leaks. The company has a proprietary platform technology which seals and facilitates healing of soft tissue wounds caused by trauma or surgical procedures. Acquired by Bard.
NextWave Pharmaceuticals is focused on developing innovative products for the pediatric pharmaceutical market. The company is developing and commercializing products that address many of the compliance, convenience, dosing and safety issues children and their parents face today. Acquired by Pfizer.
Ocera Therapeutics (NASDAQ: OCRX) is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet clinical need.
OncoGenex Pharmaceuticals (NASDAQ: OGXI) is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.
Palatin (NYSE: PTN) is developing melanocortin-based therapeutics. The company’s lead product, bremelanotide, is in Phase II clinical trials for female sexual dysfunction.
Prestwick Pharmaceuticals is a specialty pharmaceutical company engaged in the development and marketing of drugs for diseases of the CNS. Acquired by Biovail.
Rempex Pharmaceuticals is a pharmaceutical company focused on the discovery and development of new antibacterial drugs to treat multi-drug resistant bacterial pathogens. Acquired by the Medicines Company.
Sagent Pharmaceuticals (NASDAQ: SGNT) is an international specialty injectable pharmaceutical company bringing finished pharmaceutical products to the U.S. market. Acquired by Nichi-Iko Pharmaceutical Co., Ltd.
Transcept Pharmaceuticals is developing products that utilize the company’s proprietary drug delivery system. The company’s lead product, Intermezzo, has been approved by the FDA and is partnered with Purdue Pharma.
Tranzyme Pharma (NASDAQ:TZYM) is developing novel GI therapeutics.
Vicept Therapeutics is developing novel products for the treatment of rosacea and other dermatological conditions. Acquired by Allergan.
YM BioSciences (NYSE: YMI) is a pharmaceutical company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development. Acquired by Gilead Sciences.